COMPOUND PROFILE / PEPTIDES & ANALOGUES
Amycretin.
Research draftAmycretin is a single-molecule GLP-1 and amylin receptor agonist studied for obesity.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Amycretin is a single-molecule GLP-1 and amylin receptor agonist studied for obesity.
Mechanism
It combines incretin and amylin-related satiety signalling.
Human research
Randomised early human trials reported weight reduction. Oral and subcutaneous formulations must be assessed separately.
Preclinical & other research
Receptor and animal work supports the dual-action rationale.
Safety & unknowns
Gastrointestinal tolerability and longer-term outcomes require continued assessment.
Regulatory status
Investigational in the sources reviewed; cross-link NNC0487-0111 after identity confirmation.
Reported use & evidence
The supplied Amycretin profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.